Neuberger Berman Group LLC Lowers Holdings in Haleon plc (NYSE:HLN)

Neuberger Berman Group LLC reduced its stake in shares of Haleon plc (NYSE:HLN) by 10.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 332,462 shares of the company’s stock after selling 37,407 shares during the quarter. Neuberger Berman Group LLC’s holdings in Haleon were worth $2,736,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Hexagon Capital Partners LLC increased its stake in shares of Haleon by 107.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after purchasing an additional 2,193 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Haleon by 853.4% in the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock worth $39,000 after buying an additional 4,267 shares in the last quarter. SRS Capital Advisors Inc. lifted its stake in Haleon by 456.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock worth $45,000 after purchasing an additional 4,477 shares in the last quarter. NBC Securities Inc. acquired a new position in Haleon during the third quarter worth $82,000. Finally, Hoxton Planning & Management LLC acquired a new position in shares of Haleon during the 4th quarter valued at about $85,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Down 0.9 %

Shares of Haleon stock opened at $8.38 on Monday. Haleon plc has a 52-week low of $7.70 and a 52-week high of $8.96. The company has a 50 day moving average of $8.32 and a 200 day moving average of $8.32. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $38.26 billion, a P/E ratio of 27.93, a P/E/G ratio of 2.22 and a beta of 0.28.

Haleon (NYSE:HLN) last posted its earnings results on Wednesday, May 1st. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. Haleon had a return on equity of 13.17% and a net margin of 9.68%. As a group, research analysts forecast that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Announces Dividend

The firm also recently announced a semi-annual dividend, which was paid on Thursday, May 16th. Stockholders of record on Friday, March 15th were given a dividend of $0.1064 per share. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend was Thursday, March 14th. Haleon’s dividend payout ratio (DPR) is presently 70.00%.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of recent analyst reports. Argus reiterated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. HSBC initiated coverage on shares of Haleon in a research note on Wednesday, April 17th. They issued a “buy” rating for the company.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.